Market research
ASND Ascendis Pharma AS
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 16B
- P/E ratio
- 18.84
- Analyst target
- 303.1632
- Dividend yield
- Not available
- Beta
- 0.48
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- DK0060615755
- Market cap
- 16B
- P/E ratio
- 18.84
- Analyst target
- 303.1632
- Dividend yield
- Not available
- Beta
- 0.48
About
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Research context
Ascendis Pharma AS appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ASND discussion.
5 years, 6 months ago
Ascendis Pharma A/S is currently in a long term downtrend where the price is trading 16.7% below its 200 day moving average.
From a valuation standpoint, the stock is 39.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 809.8.
Ascendis Pharma A/S's total revenue sank by 78.7% to $535K since the same quarter in the previous year.
Its net income has dropped by 72.9% to $-139M since the same quarter in the previous year.
Finally, its free cash flow fell by 89.7% to $-96M since the same quarter in the previous year.
Based on the above factors, Ascendis Pharma A/S gets an overall score of 1/5.